BRPI0517843A - compostos de moléculas conjugadas com a atividade de absorção de células aumentada - Google Patents
compostos de moléculas conjugadas com a atividade de absorção de células aumentadaInfo
- Publication number
- BRPI0517843A BRPI0517843A BRPI0517843-6A BRPI0517843A BRPI0517843A BR PI0517843 A BRPI0517843 A BR PI0517843A BR PI0517843 A BRPI0517843 A BR PI0517843A BR PI0517843 A BRPI0517843 A BR PI0517843A
- Authority
- BR
- Brazil
- Prior art keywords
- molecule
- compounds
- increased cell
- absorption activity
- cell absorption
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1019—Tetrapeptides with the first amino acid being basic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
COMPOSTOS DE MOLéCULAS CONJUGADAS COM A ATIVIDADE DE ABSORçãO DE CéLULAS AUMENTADA. A presente invenção refere-se a uma molécula conjugada compreendendo pelo menos uma primeira porção (1) compreendendo uma sequência carreadora e pelo menos uma segunda porção (II) compreendendo pelo menos uma molécula de fármaco antitumor ou uma molécula de inibidor protease, a dita molécula conjugada compreendendo aminoácidos Denantioméricos em sua porção (1). Além disso, a invenção refere-se a composições farmacêuticas contendo a dita molécula conjugada bem como ao uso da dita molécula conjugada para tratamento terapêutico. Também são descritos métodos para melhorar a permeabilidade da célula ou solubilidade em água.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04026934A EP1656951A1 (en) | 2004-11-12 | 2004-11-12 | Conjugates with enhanced cell uptake activity |
PCT/EP2005/011991 WO2006050930A2 (en) | 2004-11-12 | 2005-11-09 | Conjugates with enhanced cell uptake activity |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0517843A true BRPI0517843A (pt) | 2008-10-21 |
Family
ID=34927367
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0517843-6A BRPI0517843A (pt) | 2004-11-12 | 2005-11-09 | compostos de moléculas conjugadas com a atividade de absorção de células aumentada |
Country Status (10)
Country | Link |
---|---|
EP (2) | EP1656951A1 (pt) |
JP (1) | JP2008519785A (pt) |
CN (1) | CN101072589A (pt) |
AR (1) | AR051765A1 (pt) |
AU (1) | AU2005303949A1 (pt) |
BR (1) | BRPI0517843A (pt) |
CA (1) | CA2585421A1 (pt) |
EA (1) | EA200700976A1 (pt) |
IL (1) | IL182760A0 (pt) |
WO (1) | WO2006050930A2 (pt) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007031098A1 (en) | 2005-09-12 | 2007-03-22 | Xigen S.A. | Cell-permeable peptide inhibitors of the jnk signal transduction pathway |
CN101583274A (zh) * | 2006-12-29 | 2009-11-18 | 雷文斯治疗公司 | 使用反向序列hiv-tat多肽的运输分子 |
BR122019000258B1 (pt) * | 2007-07-26 | 2021-09-14 | Revance Therapeutics, Inc | Composição farmacêutica ou cosmética compreendendo um peptídeo catiônico e kit para administração da mesma |
WO2009143864A1 (en) | 2008-05-30 | 2009-12-03 | Xigen S.A. | Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases |
WO2009143865A1 (en) | 2008-05-30 | 2009-12-03 | Xigen S.A. | Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases |
WO2010072228A1 (en) | 2008-12-22 | 2010-07-01 | Xigen S.A. | Novel transporter constructs and transporter cargo conjugate molecules |
WO2011069149A2 (en) | 2009-12-04 | 2011-06-09 | Dcb-Usa Llc | Cathepsin s inhibitors |
WO2011160653A1 (en) | 2010-06-21 | 2011-12-29 | Xigen S.A. | Novel jnk inhibitor molecules |
JP5857056B2 (ja) | 2010-10-14 | 2016-02-10 | ザイジェン インフラメーション エルティーディー | 慢性又は非慢性の炎症性眼疾患を治療するためのjnkシグナル伝達経路の細胞透過性ペプチド阻害剤の使用 |
WO2013091670A1 (en) | 2011-12-21 | 2013-06-27 | Xigen S.A. | Novel jnk inhibitor molecules for treatment of various diseases |
WO2014060447A1 (en) * | 2012-10-17 | 2014-04-24 | Novo Nordisk A/S | Fatty acid acylated d-amino acids for oral peptide delivery |
AU2014301631A1 (en) | 2013-06-26 | 2015-08-27 | Xigen Inflammation Ltd. | New use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various diseases |
WO2014206427A1 (en) | 2013-06-26 | 2014-12-31 | Xigen Inflammation Ltd. | New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases |
WO2015197097A1 (en) | 2014-06-26 | 2015-12-30 | Xigen Inflammation Ltd. | New use for jnk inhibitor molecules for treatment of various diseases |
EP3758730B1 (en) | 2018-02-27 | 2022-11-02 | Lipotrue, S.L. | Peptides and compositions for use in cosmetics and medicine |
CN108794581B (zh) * | 2018-06-26 | 2021-09-10 | 江苏大学 | 一种靶向结合淋巴癌细胞系的特异性d型多肽及其应用 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040152084A1 (en) * | 2003-01-31 | 2004-08-05 | Slattum Paul M. | Compounds and processes for single-pot attachment of a label to nucleic acid |
ES2210761T3 (es) * | 1997-05-21 | 2004-07-01 | The Board Of Trustees Of The Leland Stanford Junior University | Composicion y procedimiento para mejorar el transporte a traves de las membranas biologicas. |
MXPA02001857A (es) * | 1999-08-24 | 2003-07-14 | Cellgate Inc | Composiciones y metodos para incrementar la entrega de drogas a traves y dentro de tejidos epiteliales. |
US6669951B2 (en) * | 1999-08-24 | 2003-12-30 | Cellgate, Inc. | Compositions and methods for enhancing drug delivery across and into epithelial tissues |
US6610820B1 (en) * | 1999-10-12 | 2003-08-26 | University Of Lausanne | Cell-permeable peptide inhibitors of the JNK signal transduction pathway |
US20030108539A1 (en) * | 2000-02-14 | 2003-06-12 | Christophe Bonny | Cell-permeable peptide inhibitors of the JNK signal transduction pathway |
US20030091640A1 (en) * | 2001-02-08 | 2003-05-15 | Srinivasan Ramanathan | Enhanced oral and transcompartmental delivery of therapeutic or diagnostic agents |
WO2004092339A2 (en) * | 2003-04-11 | 2004-10-28 | Ilex Products, Inc. | Modulation of muc1 mediated signal transduction |
DE602004028930D1 (de) * | 2003-04-29 | 2010-10-14 | Avi Biopharma Inc | Zusammensetzungen zur verbesserung der antisense-wirksamkeit und des transports von nukleinsäureanalog in zellen |
-
2004
- 2004-11-12 EP EP04026934A patent/EP1656951A1/en active Pending
-
2005
- 2005-11-09 JP JP2007540568A patent/JP2008519785A/ja not_active Abandoned
- 2005-11-09 EP EP05811041A patent/EP1809334A2/en not_active Withdrawn
- 2005-11-09 CA CA002585421A patent/CA2585421A1/en not_active Abandoned
- 2005-11-09 CN CNA2005800387282A patent/CN101072589A/zh active Pending
- 2005-11-09 EA EA200700976A patent/EA200700976A1/ru unknown
- 2005-11-09 AU AU2005303949A patent/AU2005303949A1/en not_active Abandoned
- 2005-11-09 WO PCT/EP2005/011991 patent/WO2006050930A2/en active Application Filing
- 2005-11-09 BR BRPI0517843-6A patent/BRPI0517843A/pt not_active IP Right Cessation
- 2005-11-11 AR ARP050104743A patent/AR051765A1/es not_active Application Discontinuation
-
2007
- 2007-04-23 IL IL182760A patent/IL182760A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
IL182760A0 (en) | 2007-07-24 |
EP1656951A1 (en) | 2006-05-17 |
CA2585421A1 (en) | 2006-05-18 |
WO2006050930A3 (en) | 2007-04-26 |
WO2006050930A2 (en) | 2006-05-18 |
JP2008519785A (ja) | 2008-06-12 |
AU2005303949A1 (en) | 2006-05-18 |
AR051765A1 (es) | 2007-02-07 |
CN101072589A (zh) | 2007-11-14 |
EA200700976A1 (ru) | 2007-12-28 |
EP1809334A2 (en) | 2007-07-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0517843A (pt) | compostos de moléculas conjugadas com a atividade de absorção de células aumentada | |
BRPI0510273A (pt) | derivados de tetraazabenzo[e]azuleno e análogos destes | |
ATE524476T1 (de) | Pyrazolopyrimidine als modulatoren von caseinkinase ii (ck2) | |
DK1521593T3 (da) | Transdermale botulinumtoksinforbindelser | |
EA200700096A1 (ru) | Производные 2-карбамид-4-фенилтиазола, способ их получения и их применение в терапии | |
MXPA05008222A (es) | Metodos y composiciones para administrar agentes terapeuticos y de diagnostico. | |
BRPI0613005A8 (pt) | uso de polipeptídeos de aprotinina como veículos em conjugados farmacêuticos. | |
BR0312408A (pt) | Inibidores de peptìdeo de ligação de proteìna smac a inibidor de apoptose de proteìnas (iap) | |
BRPI0517458A (pt) | derivados da xantina com atividade para o receptor hm74a | |
GT200500237A (es) | Derivados de pirimidina | |
IS2376B (is) | Þíenópýrimidíndíón og notkun þeirra í breytingu ásjálfsnæmissjúkdómi | |
ATE470443T1 (de) | Indol-1-yl-essigsäurederivate | |
BRPI0513287A (pt) | derivados de pirido-pirimidina, sua preparação, sua aplicação em terapêutica | |
BR0305628A (pt) | Composição farmacêutica para tratar disfunção sexual num mamìfero compreendendo peptìdeo e seu uso | |
DK1290011T3 (da) | Melphalan-derivater og deres anvendelse som cancer-kemoterapeutiske lægemidler | |
Werle et al. | Evaluation and improvement of the properties of the novel cystine-knot microprotein McoEeTI for oral administration | |
BRPI0720230B8 (pt) | formulação nutricional oralmente administrável, uso da formulação, e, composição | |
BRPI0621347B8 (pt) | composição farmacêutica para aumentar a produção de eritrócitos e para o tratamento de anemia | |
BR0012757A (pt) | Conjugados e processos para produção dos mesmos, bem como seu uso para transporte de moléculas através de membranas biológicas | |
Suzuki et al. | Anthraquinone derivatives as a new family of protein photocleavers | |
BRPI0507811A (pt) | derivados de 7h-pirrolopirimidina | |
SE0300457D0 (sv) | Novel compounds | |
Park et al. | Effect of the oligo (ethylene glycol) group on the antioxidant activity of manganese salen complexes | |
BR0313019A (pt) | Compostos que se ligam a p-selectina | |
ATE505483T1 (de) | Derivate des biologisch aktiven peptids vapeehptllteaplnpk |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012. |
|
B15K | Others concerning applications: alteration of classification |
Ipc: C07K 7/06 (2006.01), A61K 47/64 (2017.01), C07K 5/ |